Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease
Oghenekome Gbinigie, Emma Ogburn, Julie Allen, Jienchi Dorward, Melissa Dobson, Dr Tracie-Ann Madden, Ly-Mee Yu, Dr David M Lowe, Professor Najib Rahman, Stavros Petrou, Duncan Richards, Kerenza Hood, Professor Mahendra G Patel, Benjamin R Saville, Joe Marion, Jane Holmes, May Ee Png, Gail Hayward, Mark Lown, Victoria Harris, Dr Bhautesh Jani, Professor Nigel Hart, Professor Saye Khoo, Heather Rutter, Jem Chalk, Joseph F Standing, Professor Judith Breuer, Layla Lavallee, Elizabeth Hadley, Lucy Cureton, Magdalena Benysek, Monique I Andersson, Nick Francis, Nicholas P B Thomas, Philip Evans, Oliver Van Hecke, Mona Koshkouei, Maria Coates, Sarah Barrett, Clare Bateman, Jennifer Davies, Ivy Raymundo-Wood, Andrew Ustianowski, Jonathan Nguyen-Van-Tam, Andrew Carson-Stevens, Richard Hobbs, Paul Little, Professor Christopher C Butler
BMJ Open, doi:10.1136/bmjopen-2022-069176
Introduction There is an urgent need to determine the safety, effectiveness and cost-effectiveness of novel antiviral treatments for COVID-19 in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. Methods and analysis PANORAMIC is a UK-wide, open-label, prospective, adaptive, multiarm platform, randomised clinical trial that evaluates antiviral treatments for COVID-19 in the community. A master protocol governs the addition of new antiviral treatments as they become available, and the introduction and cessation of existing interventions via interim analyses. The first two interventions to be evaluated are molnupiravir (Lagevrio) and nirmatrelvir/ritonavir (Paxlovid). Eligibility criteria: community-dwelling within 5 days of onset of symptomatic COVID-19 (confirmed by PCR or lateral flow test), and either (1) aged 50 years and over, or (2) aged 18-49 years with qualifying comorbidities. Registration occurs via the trial website and by telephone. Recruitment occurs remotely through the central trial team, or in person through clinical sites. Participants are randomised to receive either usual care or a trial drug plus usual care. Outcomes are collected via a participant-completed daily electronic symptom diary for 28 days post randomisation. Participants and/or their Trial Partner are contacted by the research team after days 7, 14 and 28 if the diary is not completed, or if the participant is unable to access the diary. The primary efficacy endpoint is all-cause, non-elective hospitalisation and/or death within 28 days of randomisation. Multiple prespecified interim analyses allow interventions to be stopped for futility or superiority based on prespecified decision criteria. A prospective economic evaluation is embedded within the trial.
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Supplemental material placed on this supplemental material which has been supplied by the author(s)
References
Abdelnabi, Foo, Kaptein, Zhang, Do et al., The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model, EBioMedicine
Amara, Penchala, Else, Hale, Fitzgerald et al., The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ss-d-N4-hydroxycytidine in human plasma and saliva, J Pharm Biomed Anal
Appendix E, INTERVENTION SPECIFIC APPENDICES
Background, None
Background, None
Bergwerk, Gonen, Lustig, Covid-19 breakthrough infections in vaccinated health care workers, N Engl J Med,
doi:10.1056/NEJMoa2109072Bernal, Da Silva, Musungaie, Molnupiravir for oral treatment of COVID-19 in Nonhospitalized patients, N Engl J Med,
doi:10.1056/NEJMoa2116044Berry, Connor, Lewis, The platform trial: an efficient strategy for evaluating multiple treatments, JAMA,
doi:10.1001/jama.2015.2316Butler, Connor, Lewis, Answering patient-centred questions efficiently: response-adaptive platform trials in primary care, Br J Gen Pract,
doi:10.3399/bjgp18X696569Butler, Yu, Dorward, Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, openlabel, adaptive platform trial, Lancet Respir Med,
doi:10.1016/S2213-2600(21)00310-6Care, None
Cevik, Tate, Lloyd, Maraolo, Schafers et al., SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis, Lancet Microbe
Considerations, 1 Declaration of Helsinki
Deviations, None
Dorward, Yu, Hayward, Colchicine for COVID-19 in adults in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial, medRxiv
Dorward, Yu, Hayward, Colchicine for COVID-19 in the Community (PRINCIPLE): a randomised, controlled, adaptive platform trial, Br J Gen Pract,
doi:10.3399/BJGP.2022.0083Fischer, Eron, Holman, Cohen, Fang et al., an Oral Antiviral Treatment for COVID-19, medRxiv
Gastine, Pang, Boshier, Carter, Lonsdale et al., Systematic Review and Patient-Level Meta-Analysis of SARS-CoV-2 Viral Dynamics to Model Response to Antiviral Therapies, Clin Pharmacol Ther
Gov, Uk, Vaccinations in the United Kingdom
Hammond, Bao, Simón-Campos, Nirmatrelvir for nonhospitalized adults with COVID-19. reply, N Engl J Med,
doi:10.1056/NEJMc2206277Hammond, Leister-Tebbe, Gardner, Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19, N Engl J Med
Hayward, Butler, Yu, Platform randomised trial of interventions against COVID-19 in older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 Syndromic illness in people at higher risk, BMJ Open,
doi:10.1136/bmjopen-2020-046799Herdman, Gudex, Lloyd, Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L), Qual Life Res,
doi:10.1007/s11136-011-9903-xHippisley-Cox, Coupland, Mehta, Keogh, Diaz-Ordaz et al., Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study, BMJ
Hm Treasury, The Green Book. Appraisal and Evaluation in Central Government
Imran, Arora, Asdaq, Khan, Alaqel et al., Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19, Molecules
Insurance, None
Insurance, None
Khoo, Fitzgerald, Fletcher, Ewings, Jaki et al., Optimal dose and safety of Molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study, J Antimicrob Chemother
Kim, Read, Fauci, Therapy for Early COVID-19: A Critical Need, JAMA
Laouenan, Guedj, Mentre, Clinical trial simulation to evaluate power to compare the antiviral effectiveness of two hepatitis C protease inhibitors using nonlinear mixed effect models: a viral kinetic approach, BMC Med Res Methodol
Mahase, Covid-19: Molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports, BMJ
Molnupiravir, None
Moustgaard, Clayton, Jones, Impact of blinding on estimated treatment effects in randomised clinical trials: metaepidemiological study, BMJ,
doi:10.1136/bmj.l6802Owen, Allerton, Anderson, An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19, Science
Paris, Perrin, Hamonic, Effectiveness of mRNA-BNT162b2, mRNA-1273, and Chadox1 nCoV-19 vaccines against COVID-19 in Healthcare workers: an observational study using surveillance data, Clin Microbiol Infect,
doi:10.1016/j.cmi.2021.06.043Paxlovid, None
Pfizer, Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR)
Pfizer, Pfizer's novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study
Pilishvili, Gierke, Ke, Effectiveness of mRNA Covid-19 vaccine among U.S. health care personnel, N Engl J Med,
doi:10.1056/NEJMoa2106599Policy, None
Quality, Procedures, None
Reporting, None
Saes, None
Screening, None
Serious, Breaches, None
Singh, Singh, Singh, Misra, Molnupiravir in COVID-19: A systematic review of literaturef, Diabetes Metab Syndr
Statistics, None
Stokel-Walker, The search for antivirals for covid-19, BMJ
Trial Visits, None
Trial Visits, None
Trial, Group, Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial, Lancet,
doi:10.1016/S0140-6736(21)00461-XTrial, Procedures, None
Van Hout, Janssen, Feng, Kohlmann, Busschbach et al., Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets, Value Health
Woodcock, Lavange, Master protocols to study multiple therapies, multiple diseases, or both, N Engl J Med,
doi:10.1056/NEJMra1510062Yu, Bafadhel, Dorward, Hayward, Saville et al., Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial, Lancet
Yu, Bafadhel, Dorward, Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial, Medrxiv
{ 'indexed': {'date-parts': [[2023, 9, 18]], 'date-time': '2023-09-18T12:27:34Z', 'timestamp': 1695040054678},
'reference-count': 36,
'publisher': 'BMJ',
'issue': '8',
'license': [ { 'start': { 'date-parts': [[2023, 8, 7]],
'date-time': '2023-08-07T00:00:00Z',
'timestamp': 1691366400000},
'content-version': 'unspecified',
'delay-in-days': 6,
'URL': 'https://creativecommons.org/licenses/by/4.0/'}],
'funder': [ {'name': 'NIHR Applied Research Collaboration', 'award': ['N/A']},
{'name': 'NIHR Advanced Fellowship', 'award': ['N/A']},
{'name': 'Northern Ireland Clinical Research Network, Public Health Agency', 'award': ['N/A']},
{ 'DOI': '10.13039/100010269',
'name': 'Wellcome Trust',
'doi-asserted-by': 'publisher',
'award': ['PhD Programme for Primary Care Clinicians - 216421']},
{ 'DOI': '10.13039/100014013',
'name': 'UK Research and Innovation',
'doi-asserted-by': 'publisher',
'award': ['UKRI/NIHR - Grant number NIHR135366']},
{ 'name': 'NIHR Health Protection Research Unit on Health Care Associated Infections and '
'Antimicrobial Resistance',
'award': ['N/A']},
{ 'DOI': '10.13039/501100000265',
'name': 'Medical Research Council',
'doi-asserted-by': 'publisher',
'award': ['COVID modelling grant, Grant number MR/W015560/1']},
{'name': 'NIHR Senior Investigator', 'award': ['N/A']},
{ 'name': 'European Clinical Research Alliance on Infectious Diseases',
'award': ['ECRAID-Prime. Grant number 101046109']},
{ 'DOI': '10.13039/501100023233',
'name': 'NIHR Applied Research Collaboration Oxford and Thames Valley',
'doi-asserted-by': 'crossref',
'award': ['N/A']},
{ 'name': 'NIHR Community Healthcare Medtech and In-Vitro Diagnostics Co-operative',
'award': ['N/A']},
{'name': 'NIHR Development and Skills Enhancement Award', 'award': ['N/A']}],
'content-domain': {'domain': ['bmj.com'], 'crossmark-restriction': True},
'published-print': {'date-parts': [[2023, 8]]},
'abstract': '<jats:sec><jats:title>Introduction</jats:title><jats:p>There is an urgent need to determine '
'the safety, effectiveness and cost-effectiveness of novel antiviral treatments for COVID-19 '
'in vaccinated patients in the community at increased risk of morbidity and mortality from '
'COVID-19.</jats:p></jats:sec><jats:sec><jats:title>Methods and '
'analysis</jats:title><jats:p>PANORAMIC is a UK-wide, open-label, prospective, adaptive, '
'multiarm platform, randomised clinical trial that evaluates antiviral treatments for COVID-19 '
'in the community. A master protocol governs the addition of new antiviral treatments as they '
'become available, and the introduction and cessation of existing interventions via interim '
'analyses. The first two interventions to be evaluated are molnupiravir (Lagevrio) and '
'nirmatrelvir/ritonavir (Paxlovid). Eligibility criteria: community-dwelling within 5\u2009'
'days of onset of symptomatic COVID-19 (confirmed by PCR or lateral flow test), and either (1) '
'aged 50 years and over, or (2) aged 18–49 years with qualifying comorbidities. Registration '
'occurs via the trial website and by telephone. Recruitment occurs remotely through the '
'central trial team, or in person through clinical sites. Participants are randomised to '
'receive either usual care or a trial drug plus usual care. Outcomes are collected via a '
'participant-completed daily electronic symptom diary for 28 days post randomisation. '
'Participants and/or their Trial Partner are contacted by the research team after days 7, 14 '
'and 28 if the diary is not completed, or if the participant is unable to access the diary. '
'The primary efficacy endpoint is all-cause, non-elective hospitalisation and/or death within '
'28 days of randomisation. Multiple prespecified interim analyses allow interventions to be '
'stopped for futility or superiority based on prespecified decision criteria. A prospective '
'economic evaluation is embedded within the '
'trial.</jats:p></jats:sec><jats:sec><jats:title>Ethics and '
'dissemination</jats:title><jats:p>Ethical approval granted by South Central–Berkshire REC '
'number: 21/SC/0393; IRAS project ID: 1004274. Results will be presented to policymakers and '
'at conferences, and published in peer-reviewed '
'journals.</jats:p></jats:sec><jats:sec><jats:title>Trial registration '
'number</jats:title><jats:p><jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" '
'ext-link-type="isrctn" xlink:href="ISRCTN30448031">ISRCTN30448031</jats:ext-link>; EudraCT '
'number: 2021-005748-31.</jats:p></jats:sec>',
'DOI': '10.1136/bmjopen-2022-069176',
'type': 'journal-article',
'created': {'date-parts': [[2023, 8, 7]], 'date-time': '2023-08-07T17:40:19Z', 'timestamp': 1691430019000},
'page': 'e069176',
'update-policy': 'http://dx.doi.org/10.1136/crossmarkpolicy',
'source': 'Crossref',
'is-referenced-by-count': 1,
'title': 'Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community '
'(PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of '
'community novel antiviral treatment of COVID-19 in people at increased risk of more severe '
'disease',
'prefix': '10.1136',
'volume': '13',
'clinical-trial-number': [{'clinical-trial-number': 'isrctn30448031', 'registry': '10.18810/isrctn'}],
'author': [ { 'ORCID': 'http://orcid.org/0000-0002-2963-4491',
'authenticated-orcid': False,
'given': 'Oghenekome',
'family': 'Gbinigie',
'sequence': 'first',
'affiliation': []},
{'given': 'Emma', 'family': 'Ogburn', 'sequence': 'additional', 'affiliation': []},
{'given': 'Julie', 'family': 'Allen', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-6072-1430',
'authenticated-orcid': False,
'given': 'Jienchi',
'family': 'Dorward',
'sequence': 'additional',
'affiliation': []},
{'given': 'Melissa', 'family': 'Dobson', 'sequence': 'additional', 'affiliation': []},
{'given': 'Tracie-Ann', 'family': 'Madden', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ly-Mee', 'family': 'Yu', 'sequence': 'additional', 'affiliation': []},
{'given': 'David M', 'family': 'Lowe', 'sequence': 'additional', 'affiliation': []},
{'given': 'Najib', 'family': 'Rahman', 'sequence': 'additional', 'affiliation': []},
{'given': 'Stavros', 'family': 'Petrou', 'sequence': 'additional', 'affiliation': []},
{'given': 'Duncan', 'family': 'Richards', 'sequence': 'additional', 'affiliation': []},
{'given': 'Kerenza', 'family': 'Hood', 'sequence': 'additional', 'affiliation': []},
{'given': 'Mahendra', 'family': 'Patel', 'sequence': 'additional', 'affiliation': []},
{'given': 'Benjamin R', 'family': 'Saville', 'sequence': 'additional', 'affiliation': []},
{'given': 'Joe', 'family': 'Marion', 'sequence': 'additional', 'affiliation': []},
{'given': 'Jane', 'family': 'Holmes', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-5876-9363',
'authenticated-orcid': False,
'given': 'May Ee',
'family': 'Png',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0003-0852-627X',
'authenticated-orcid': False,
'given': 'Gail',
'family': 'Hayward',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-8309-568X',
'authenticated-orcid': False,
'given': 'Mark',
'family': 'Lown',
'sequence': 'additional',
'affiliation': []},
{'given': 'Victoria', 'family': 'Harris', 'sequence': 'additional', 'affiliation': []},
{'given': 'Bhautesh', 'family': 'Jani', 'sequence': 'additional', 'affiliation': []},
{'given': 'Nigel', 'family': 'Hart', 'sequence': 'additional', 'affiliation': []},
{'given': 'Saye', 'family': 'Khoo', 'sequence': 'additional', 'affiliation': []},
{'given': 'Heather', 'family': 'Rutter', 'sequence': 'additional', 'affiliation': []},
{'given': 'Jem', 'family': 'Chalk', 'sequence': 'additional', 'affiliation': []},
{'given': 'Joseph F', 'family': 'Standing', 'sequence': 'additional', 'affiliation': []},
{'given': 'Judith', 'family': 'Breuer', 'sequence': 'additional', 'affiliation': []},
{'given': 'Layla', 'family': 'Lavallee', 'sequence': 'additional', 'affiliation': []},
{'given': 'Elizabeth', 'family': 'Hadley', 'sequence': 'additional', 'affiliation': []},
{'given': 'Lucy', 'family': 'Cureton', 'sequence': 'additional', 'affiliation': []},
{'given': 'Magdalena', 'family': 'Benysek', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0003-0619-1074',
'authenticated-orcid': False,
'given': 'Monique I',
'family': 'Andersson',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-8939-7312',
'authenticated-orcid': False,
'given': 'Nick',
'family': 'Francis',
'sequence': 'additional',
'affiliation': []},
{'given': 'Nicholas P B', 'family': 'Thomas', 'sequence': 'additional', 'affiliation': []},
{'given': 'Philip', 'family': 'Evans', 'sequence': 'additional', 'affiliation': []},
{'given': 'Oliver', 'family': 'van Hecke', 'sequence': 'additional', 'affiliation': []},
{'given': 'Mona', 'family': 'Koshkouei', 'sequence': 'additional', 'affiliation': []},
{'given': 'Maria', 'family': 'Coates', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sarah', 'family': 'Barrett', 'sequence': 'additional', 'affiliation': []},
{'given': 'Clare', 'family': 'Bateman', 'sequence': 'additional', 'affiliation': []},
{'given': 'Jennifer', 'family': 'Davies', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ivy', 'family': 'Raymundo-Wood', 'sequence': 'additional', 'affiliation': []},
{'given': 'Andrew', 'family': 'Ustianowski', 'sequence': 'additional', 'affiliation': []},
{'given': 'Jonathan', 'family': 'Nguyen-Van-Tam', 'sequence': 'additional', 'affiliation': []},
{'given': 'Andrew', 'family': 'Carson-Stevens', 'sequence': 'additional', 'affiliation': []},
{'given': 'Richard', 'family': 'Hobbs', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0003-3664-1873',
'authenticated-orcid': False,
'given': 'Paul',
'family': 'Little',
'sequence': 'additional',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-0102-3453',
'authenticated-orcid': False,
'given': 'Christopher C',
'family': 'Butler',
'sequence': 'additional',
'affiliation': []}],
'member': '239',
'published-online': {'date-parts': [[2023, 8, 7]]},
'reference': [ { 'key': '2023080710400934000_13.8.e069176.1',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMoa2109072'},
{ 'key': '2023080710400934000_13.8.e069176.2',
'doi-asserted-by': 'crossref',
'first-page': '1699',
'DOI': '10.1016/j.cmi.2021.06.043',
'article-title': 'Effectiveness of mRNA-BNT162b2, mRNA-1273, and Chadox1 nCoV-19 vaccines '
'against COVID-19 in Healthcare workers: an observational study using '
'surveillance data',
'volume': '27',
'author': 'Paris',
'year': '2021',
'journal-title': 'Clin Microbiol Infect'},
{ 'key': '2023080710400934000_13.8.e069176.3',
'doi-asserted-by': 'crossref',
'unstructured': 'Pilishvili T , Gierke R , Fleming-Dutra KE , et al . Effectiveness of '
'mRNA Covid-19 vaccine among U.S. health care personnel. N Engl J Med '
'2021;385. doi:10.1056/NEJMoa2106599',
'DOI': '10.1056/NEJMoa2106599'},
{ 'key': '2023080710400934000_13.8.e069176.4',
'unstructured': 'The Telegraph . Covid hospital admissions are surging again – is this '
'the start of a new wave. 2022. Available: '
'https://www.telegraph.co.uk/global-health/science-and-disease/covid-hospital-admissions-surging-start-new-wave/'},
{ 'key': '2023080710400934000_13.8.e069176.5',
'doi-asserted-by': 'crossref',
'first-page': '1010',
'DOI': '10.1016/S2213-2600(21)00310-6',
'article-title': 'Doxycycline for community treatment of suspected COVID-19 in people at '
'high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, '
'controlled, open-label, adaptive platform trial',
'volume': '9',
'author': 'Butler',
'year': '2021',
'journal-title': 'Lancet Respir Med'},
{ 'key': '2023080710400934000_13.8.e069176.6',
'doi-asserted-by': 'crossref',
'unstructured': 'PRINCIPLE Trial Collaborative Group . Azithromycin for community '
'treatment of suspected COVID-19 in people at increased risk of an '
'adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, '
'open-label, adaptive platform trial. Lancet 2021;397:1063. '
'doi:10.1016/S0140-6736(21)00461-X',
'DOI': '10.1016/S0140-6736(21)00461-X'},
{ 'key': '2023080710400934000_13.8.e069176.7',
'unstructured': 'Yu L-M , Bafadhel M , Dorward J , et al . Inhaled budesonide for '
'COVID-19 in people at higher risk of adverse outcomes in the community: '
'interim analyses from the PRINCIPLE trial. Medrxiv 2021.'},
{ 'key': '2023080710400934000_13.8.e069176.8',
'doi-asserted-by': 'publisher',
'DOI': '10.1056/NEJMoa2021436'},
{ 'key': '2023080710400934000_13.8.e069176.9',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41594-021-00657-8'},
{ 'key': '2023080710400934000_13.8.e069176.10',
'unstructured': 'Pfizer . Pfizer’s novel COVID-19 oral antiviral treatment candidate '
'reduced risk of hospitalization or death by 89% in interim analysis of '
'phase 2/3 EPIC-HR study. 2021. Available: '
'https://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate'},
{ 'key': '2023080710400934000_13.8.e069176.11',
'doi-asserted-by': 'crossref',
'unstructured': 'Extance A . Covid-19: what is the evidence for the antiviral paxlovid? '
'BMJ 2022;377:1037. doi:10.1136/bmj.o1037',
'DOI': '10.1136/bmj.o1037'},
{ 'key': '2023080710400934000_13.8.e069176.12',
'doi-asserted-by': 'crossref',
'unstructured': 'Singh AK , Singh A , Singh R , et al . Molnupiravir in COVID-19: a '
'systematic review of literature. Diabetes Metab Syndr 2021;15:102329. '
'doi:10.1016/j.dsx.2021.102329',
'DOI': '10.1016/j.dsx.2021.102329'},
{ 'key': '2023080710400934000_13.8.e069176.13',
'first-page': '475',
'article-title': 'Nirmatrelvir for nonhospitalized adults with COVID-19. reply',
'volume': '387',
'author': 'Hammond',
'year': '2022',
'journal-title': 'N Engl J Med'},
{ 'key': '2023080710400934000_13.8.e069176.14',
'doi-asserted-by': 'publisher',
'DOI': '10.1001/jama.2015.2316'},
{ 'key': '2023080710400934000_13.8.e069176.15',
'doi-asserted-by': 'publisher',
'DOI': '10.3399/bjgp18X696569'},
{ 'key': '2023080710400934000_13.8.e069176.16',
'unstructured': 'National Institute for Health and Care Excellence . COVID-19 rapid '
'guideline: managing COVID-19. 2021. Available: '
'https://www.nice.org.uk/guidance/ng191'},
{ 'key': '2023080710400934000_13.8.e069176.17',
'doi-asserted-by': 'crossref',
'first-page': '62',
'DOI': '10.1056/NEJMra1510062',
'article-title': 'Master protocols to study multiple therapies, multiple diseases, or '
'both',
'volume': '377',
'author': 'Woodcock',
'year': '2017',
'journal-title': 'N Engl J Med'},
{ 'key': '2023080710400934000_13.8.e069176.18',
'doi-asserted-by': 'crossref',
'unstructured': 'Butler C , Hobbs FDR , Gbinigie O , et al . Molnupiravir plus usual care '
'versus usual care alone as early treatment for adults with COVID-19 at '
'increased risk of adverse outcomes (PANORAMIC): an open-label, '
'platform-adaptive randomised controlled trial. SSRN Journal 2022. '
'doi:10.2139/ssrn.4237902',
'DOI': '10.2139/ssrn.4237902'},
{ 'key': '2023080710400934000_13.8.e069176.19',
'unstructured': 'University of Oxford Primary Care Clinical Trials Unit . PANORAMIC trial '
'2021. Available: https://www.panoramictrial.org/'},
{ 'key': '2023080710400934000_13.8.e069176.20',
'unstructured': 'UK Health Security Agency . People with symptoms of a respiratory '
'infection including COVID-19. 2022. Available: '
'https://www.gov.uk/guidance/people-with-symptoms-of-a-respiratory-infection-including-covid-19#what-to-do-if-you-have-a-positive-covid-19-test-result'},
{ 'key': '2023080710400934000_13.8.e069176.21',
'doi-asserted-by': 'publisher',
'DOI': '10.1007/s11136-011-9903-x'},
{ 'key': '2023080710400934000_13.8.e069176.22',
'doi-asserted-by': 'crossref',
'unstructured': 'Moustgaard H , Clayton GL , Jones HE , et al . n.d. Impact of blinding '
'on estimated treatment effects in randomised clinical trials: '
'meta-epidemiological study. BMJ:l6802. doi:10.1136/bmj.l6802',
'DOI': '10.1136/bmj.l6802'},
{ 'key': '2023080710400934000_13.8.e069176.23',
'doi-asserted-by': 'crossref',
'unstructured': 'Anand R , Norrie J , Bradley JM , et al . Fool’s gold? Why blinded '
'trials are not always best. BMJ 2020;368:l6228. doi:10.1136/bmj.l6228',
'DOI': '10.1136/bmj.l6228'},
{ 'key': '2023080710400934000_13.8.e069176.24',
'unstructured': 'National Institute for Health and Care Excellence . COVID-19 rapid '
'guideline: managing COVID-19 [NG191]. 2021. Available: '
'https://www.nice.org.uk/guidance/ng191'},
{ 'key': '2023080710400934000_13.8.e069176.25',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.jval.2012.02.008'},
{ 'key': '2023080710400934000_13.8.e069176.26',
'doi-asserted-by': 'crossref',
'first-page': '509',
'DOI': '10.1056/NEJMoa2116044',
'article-title': 'Molnupiravir for oral treatment of COVID-19 in Nonhospitalized patients',
'volume': '386',
'author': 'Jayk Bernal',
'year': '2022',
'journal-title': 'N Engl J Med'},
{ 'key': '2023080710400934000_13.8.e069176.27',
'unstructured': 'GOV.UK . Vaccinations in the United Kingdom 2022. Available: '
'https://coronavirus.data.gov.uk/details/vaccinations'},
{ 'key': '2023080710400934000_13.8.e069176.28',
'unstructured': 'Merck . Merck and Ridgeback’s investigational oral antiviral '
'Molnupiravir reduced the risk of hospitalization or death by '
'approximately 50 percent compared to placebo for patients with mild or '
'moderate COVID-19 in positive interim analysis of phase 3 study 2021. '
'Available: '
'https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/'},
{ 'key': '2023080710400934000_13.8.e069176.29',
'doi-asserted-by': 'crossref',
'unstructured': 'Burki TK . Omicron variant and booster COVID-19 vaccines. Lancet Respir '
'Med 2022;10. doi:10.1016/S2213-2600(21)00559-2',
'DOI': '10.1016/S2213-2600(21)00559-2'},
{ 'key': '2023080710400934000_13.8.e069176.30',
'doi-asserted-by': 'crossref',
'unstructured': 'Hayward G , Butler CC , Yu L-M , et al . Platform randomised trial of '
'interventions against COVID-19 in older peoPLE (PRINCIPLE): protocol for '
'a randomised, controlled, open-label, adaptive platform, trial of '
'community treatment of COVID-19 Syndromic illness in people at higher '
'risk. BMJ Open 2021;11:e046799. doi:10.1136/bmjopen-2020-046799',
'DOI': '10.1136/bmjopen-2020-046799'},
{ 'key': '2023080710400934000_13.8.e069176.31',
'unstructured': 'Office for National Statistics . 2011 census 2011. 2011. Available: '
'https://www.nomisweb.co.uk/census/2011/data_finder'},
{ 'key': '2023080710400934000_13.8.e069176.32',
'unstructured': 'National Institute for Health and Care Excellence . COVID-19 rapid '
'guideline: managing the long-term effects of COVID-19. 2020. Available: '
'https://www.nice.org.uk/guidance/NG188'},
{ 'key': '2023080710400934000_13.8.e069176.33',
'doi-asserted-by': 'crossref',
'unstructured': 'Greenhalgh T , Knight M , A’Court C , et al . Management of post-acute '
'COVID-19 in primary care. BMJ:m3026. doi:10.1136/bmj.m3026',
'DOI': '10.1136/bmj.m3026'},
{ 'key': '2023080710400934000_13.8.e069176.34',
'doi-asserted-by': 'crossref',
'unstructured': 'Cirulli ET , Schiabor Barrett KM , Riffle S , et al . Long-term COVID-19 '
'symptoms in a large unselected population. Infectious Diseases (except '
'HIV/AIDS) 2020. doi:10.1101/2020.10.07.20208702',
'DOI': '10.1101/2020.10.07.20208702'},
{ 'key': '2023080710400934000_13.8.e069176.35',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.ctim.2004.07.043'},
{ 'key': '2023080710400934000_13.8.e069176.36',
'doi-asserted-by': 'publisher',
'DOI': '10.3399/BJGP.2022.0083'}],
'container-title': 'BMJ Open',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1136/bmjopen-2022-069176',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2023, 8, 7]],
'date-time': '2023-08-07T17:40:57Z',
'timestamp': 1691430057000},
'score': 1,
'resource': {'primary': {'URL': 'https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2022-069176'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2023, 8]]},
'references-count': 36,
'journal-issue': { 'issue': '8',
'published-online': {'date-parts': [[2023, 8, 7]]},
'published-print': {'date-parts': [[2023, 8]]}},
'alternative-id': ['10.1136/bmjopen-2022-069176'],
'URL': 'http://dx.doi.org/10.1136/bmjopen-2022-069176',
'relation': {},
'ISSN': ['2044-6055', '2044-6055'],
'subject': ['General Medicine'],
'container-title-short': 'BMJ Open',
'published': {'date-parts': [[2023, 8]]}}
